Lentiginous melanoma in situ treatment with topical imiquimod: Need for individualized regimens

Archives of Dermatology

Volumn 146, Issue 11, 2010, Pages 1309-1310

  Missall, Tricia A ^a   Hurley, M Yadira ^a   Fosko, Scott W ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LENTIGINOSIS; LENTIGINOUS MELANOMA; MALE; MELANOMA; PATIENT CARE; PRIORITY JOURNAL; PUNCH BIOPSY; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 78349268372     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.338     Document Type: Article

References (3)

1. Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol. 2005;125(4):685-691.
2. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493-504.
3. Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160(5):994-998.